Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “neutral” rating reaffirmed by stock analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They currently have a $4.00 target price on the stock. Wedbush’s price target would indicate a potential upside of 80.18% from the company’s previous close.

Several other research firms also recently commented on ZNTL. Guggenheim dropped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Trading Down 3.5 %

Zentalis Pharmaceuticals stock traded down $0.08 during trading on Friday, hitting $2.22. The company had a trading volume of 2,468,833 shares, compared to its average volume of 2,124,194. The stock has a market cap of $158.20 million, a price-to-earnings ratio of -0.89 and a beta of 1.86. Zentalis Pharmaceuticals has a 1-year low of $2.13 and a 1-year high of $18.07. The company’s 50 day simple moving average is $3.07 and its 200-day simple moving average is $3.36.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.36. As a group, analysts forecast that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Verition Fund Management LLC boosted its position in Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after buying an additional 399,745 shares in the last quarter. GSA Capital Partners LLP grew its stake in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after acquiring an additional 353,384 shares during the last quarter. Primecap Management Co. CA increased its holdings in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after acquiring an additional 265,690 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock worth $843,000 after acquiring an additional 127,868 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.